Search Results
Aug 11, 2026, 06:30 ET Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
data.Additional Phase 2 CALLIPER Data Presented at CMSC Annual Meeting: Presented one late-breaking and two additional posters of new data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The new analyses, which
More news about: Immunic, Inc.
May 28, 2026, 06:30 ET Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
activator, vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, taking place May 27-29, 2026 in Charlotte, NC. All poster presentations will be accessible on the "Events and Presentations" section
More news about: Immunic, Inc.
Apr 30, 2026, 06:30 ET Immunic to Participate in Investor and Medical Conferences in May
[email protected] 27-29: 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in Charlotte, NC. One late-breaking poster
More news about: Immunic, Inc.
Jan 21, 2026, 06:00 ET Yuchai Participates in Guangxi Yuchai Double Growth Fund
Governmental Entities") and China Merchants Securities Capital Investment Company Limited ("CMSC"). CMSC is the sole general partner and fund manager of the Growth Fund. Each of Yuchai, the Two Government Entities and CMSC holds 33.3%, 41.7% (in aggregate) and 25.0% interest in the Growth Fund. The
More news about: China Yuchai International
Jan 07, 2026, 06:30 ET Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Neuroimmunology (ISNI), the 11th Congress of the European Academy of Neurology (EAN) – Helsinki 2025, the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025, the American Academy of Neurology (AAN) 2025 Annual Meeting and the Americas Committee for Treatment and Research in Multiple
More news about: Immunic, Inc.
Nov 03, 2025, 17:31 ET Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion During the Forecast Period (2025-2034) Due to Strong Pipeline and Advanced Therapeutic Strategies | DelveInsight
investigational BTK inhibitor, from the Phase II FENopta open-label extension (OLE) study, were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Phoenix, Arizona. What is Chronic Progressive Multiple Sclerosis?
More news about: DelveInsight Business Research, LLP
Sep 18, 2025, 10:22 ET National Multiple Sclerosis Society Leads the Way in Making it Easier to Diagnose MS
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis"Visual System: "
More news about: National Multiple Sclerosis Society
Sep 17, 2025, 10:15 ET Global System-on-Chip Design Service Market Set to Reach $5.5 Billion by 2031, Driven by Automotive and Consumer Electronics Demand | Valuates Reports
industries.CoAsia SEMI – Offers end-to-end SoC and ASIC design services, including advanced process node expertise and IP integration.CMSC Inc – Specializes in SoC architecture, digital design, and system-level verification for high-performance computing and embedded systems.Cadence
More news about: Valuates Reports